|
Early analyst calls (DNA) (JNJ) |
|
| Aug 15, 2008 07:20 AM UTC |
|
Tracked Blogger
|
Via BloggingStocks:
Filed under: Before the bell, Analyst upgrades and downgrades, Johnson and Johnson (JNJ), Genentech Inc (DNA) Goldman Sachs downgraded Daimler (NYSE:DAI) to Neutral from Buy, according to MarketWatch. Citigroup downgraded Genentech (NYSE:DNA) to Hold from Buy, according to Briefing.com. The news service also writes that UBS downgraded Johnson & Johnson (NYSE:JNJ) to Hold from Buy. Priceline.com (NASDAQ:PCLN) was raised to Buy at Citigroup, according to 24/7 Wall St. The financial site also reports that Harman (NYSE:HAR) was cut to Neutral at Baird. Douglas A. McIntyre Read | Permalink | Email this | Comments<map name="google_ad_map_145-1285427"><area href="http://imageads.googleadservices.com/pagead/imgclick/145-1285427?pos=0" shape="rect" coords="1,2,367,28" /><area href="http://services.google.com/feedback/abg" shape="rect" coords="384,10,453,23" /></map> 
Read the rest of original post »
|
Be the first to comment on this story and earn 2 points.
|
|
IN THE PRESS |
|
|
|
|
|
|
| About | RSS | Feedback | Contact Us | Terms of Service | Privacy |
© 2009 FinancialContent Services, Inc. |
|
Data powered by FinancialContent. All Rights Reserved. Quotes delayed at least 20 minutes unless otherwise indicated. |
|
None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. |
